Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC
NCT07692048Phase 1Not yet recruiting
- Sponsor
- Sichuan University
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CPO301 in non-small cell lung cancer (NSCLC), sponsored by Sichuan University. Primary endpoint: Incidence of adverse events at 3.5 years. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
CPO301
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07692048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07692048.